AMBLER, Pa., May 13, 2021 /PRNewswire/ -- Simplex Health, the leading provider of evidence-based medical nutrition therapies, and Axia Women's Health, one of the nation's largest independent women's health groups announce an expanded partnership to support gestational diabetes patients across Pennsylvania, New Jersey, Indiana, Ohio, and Kentucky. Simplex Health will work as a trusted partner to 400 providers within Axia – helping patients manage and improve their condition through Simplex's proprietary Low-Insulin Nutrition Interventions. The announcement comes on the heels of a successful two-year relationship with practices throughout Montgomery County, PA.
Search / 153 results found Showing: 1-10 of 153
Isla Fisher was nervous about filming 'Blithe Spirit' with Dame Judi Dench but the screen legend put her at ease by telling a "really dirty joke".
Jessica Alba found turning 40 a "weird" experience but her perspective on the milestone age has changed.
On Thursday, May 6, 2021 at 11:00 a.m. E.T., Rep. Carolyn B. Maloney, the Chairwoman of the Committee on Oversight and Reform, and Committee M…
‘Black women are subjected to harsh and racist treatment during pregnancy and childbirth. … Black women die because the system denies our humanity.'
Kendall Jenner suffered from "very bad panic attacks" two or three years ago.
Khloé Kardashian has had doubts about surrogacy even though she's been warned against carrying another child.
ABBOTTSTOWN, Pa., May 3, 2021 /PRNewswire-PRWeb/ -- Innovo Detox has earned The Joint Commission's Gold Seal of Approval® for Comprehensive Accreditation Manual for Behavioral Health Care and Human Services Accreditation by demonstrating continuous compliance with its performance standards. The Gold Seal is a symbol of quality that reflects a health care organization's commitment to providing safe and quality patient care.
If you enjoy spending time outdoors during the warmer months, it’s inevitable that you will run into pesky plants or annoying insects, especia…
KING OF PRUSSIA, Pa., April 29, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The approval, based on data from the PATH (Polyneuropathy And Treatment with Hizentra) Extension study, simplifies dosage adjustments between two safe and effective doses proven to prevent CIDP relapse - without the need for intravenous immune globulin treatment in the event of a relapse on the low dose. The PATH Extension study was a multicenter, open-label extension study to the Phase III PATH study that evaluated the long-term safety and efficacy of Hizentra 0.2 g/kg and 0.4 g/kg weekly doses in the maintenance treatment of CIDP.